TAK228(Takeda)은 CD30 표적 ADC로, Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic; Classical Hodgkin Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: targeting key metabolic pathway. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 2.5% (ClinicalTrials.gov NCT02197572). 차별점: novel combination therapy could be added to standard upfront therapies or used as a salvage therapy for relapsed disease to i.
CD30
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic; Classical Hodgkin Lymphoma
Discontinued
ADC) trastuzumab-emtansine (T-DM1) remains unexplored
DM1 in HER2-Positive Breast Cancer
novel combination therapy could be added to standard upfront therapies or used as a salvage therapy for relapsed disease to i
targeting key metabolic pathway
apoptosis
PD-L1 expression
resistance to treatments targeting key metabolic pathways, which represents a significant challenge in personalized cancer therapy fo
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
TAK228(Takeda)은 CD30 표적 ADC로, Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic; Classical Hodgkin Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: targeting key metabolic pathway. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 2.5% (ClinicalTrials.gov NCT02197572). 차별점: novel combination therapy could be added to standard upfront therapies or used as a salvage therapy for relapsed disease to i.
CD30
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic; Classical Hodgkin Lymphoma
Discontinued
ADC) trastuzumab-emtansine (T-DM1) remains unexplored
DM1 in HER2-Positive Breast Cancer
novel combination therapy could be added to standard upfront therapies or used as a salvage therapy for relapsed disease to i
targeting key metabolic pathway
apoptosis
PD-L1 expression
resistance to treatments targeting key metabolic pathways, which represents a significant challenge in personalized cancer therapy fo
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.